<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835142</url>
  </required_header>
  <id_info>
    <org_study_id>KL140-Ⅲ-02-CTP</org_study_id>
    <nct_id>NCT04835142</nct_id>
  </id_info>
  <brief_title>Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC</brief_title>
  <official_title>Phase III Clinical Study Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in&#xD;
      the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, a multicenter, randomized, double-blind, controlled trial design was used to&#xD;
      compare the efficacy and safety of A140 or Erbitux combined with mfolfox6 regimen in the&#xD;
      first-line treatment of Ras wild-type metastatic colorectal cancer patients&#xD;
&#xD;
      Objective to compare the 12 week objective response rate (ORR) of A140 and ebitur combined&#xD;
      with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal&#xD;
      cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The objective tumor response rate (ORR) of colorectal cancer patients at 12 weeks based on the evaluation of the independent imaging evaluation committee, and confirmed at least 4 weeks later</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>16 Weeks</time_frame>
    <description>1)Based on the researcher's assessment of the objective tumor response rate (ORR) of patients with colorectal cancer after 12 weeks of medication, and confirmed at least 4 weeks later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS-1 year</time_frame>
    <description>2)PFS within 1 year after medication based on the evaluation by the independent imaging evaluation committee and the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>OS-1year</time_frame>
    <description>2) OS within 1 year after medication based on the evaluation by the independent imaging evaluation committee and the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS-1 year after the last patient's first dose</time_frame>
    <description>3)Based on the researcher's assessment of PFS after 1 year of medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>OS-1 year after the last patient's first dose</time_frame>
    <description>3)Based on the researcher's assessment of OS after 1 year of medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">686</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Double blind control period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experiment arm： All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.&#xD;
control arm: All eligible subjects will receive Erbitux in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open single period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double blind control period A140</intervention_name>
    <description>experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)</description>
    <arm_group_label>Double blind control period</arm_group_label>
    <other_name>KL-140</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open single period A140</intervention_name>
    <description>Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)</description>
    <arm_group_label>Open single period</arm_group_label>
    <other_name>KL-140</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be able to understand the procedures and methods of this study, be willing to strictly&#xD;
             abide by the clinical trial protocol to complete this trial, and sign the informed&#xD;
             consent voluntarily&#xD;
&#xD;
          -  Male or female subjects aged 18-75 years (including 18 and 75 years)&#xD;
&#xD;
          -  Histologically proven diagnosis of metastatic colorectal cancer. No previous systemic&#xD;
             chemotherapy for metastatic colorectal cancer. Patients who have completed adjuvant&#xD;
             chemotherapy before the start of the study can be enrolled, Platinum containing&#xD;
             chemotherapy needs to end for more than 12 months, and non platinum containing&#xD;
             chemotherapy needs to end for more than 6 months;&#xD;
&#xD;
          -  KRAS and NRAS genotypes in tumor tissues were wild type, and BRAF-V600E mutation was&#xD;
             not found；&#xD;
&#xD;
          -  At least one measurable lesion by computer tomography(CT) or magnetic resonance&#xD;
             imaging (MRI)according to RECIST1.1 criteria (not in an irradiated area)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG)performance status of 0 or 1 at trial entry；&#xD;
&#xD;
          -  Life expectancy of at least 16 weeks；&#xD;
&#xD;
          -  The level of organ function before the first medication met the following&#xD;
             requirements:&#xD;
&#xD;
               1. Peripheral blood cell count: leukocyte count ≥ 3×10ˆ9 / L, neutrophil count ≥&#xD;
                  1.5× 10ˆ9 / L, platelet count ≥ 75 × 10ˆ9 / L, hemoglobin ≥ 90 g / L;&#xD;
&#xD;
               2. Liver function: total bilirubin ≤ 1.5 ULN, Aspartate transaminase (AST) and&#xD;
                  alanine transaminase (ALT) ≤ 2.5 ULN; AST and ALT≤ 5 ULN in subjects with liver&#xD;
                  metastasis;&#xD;
&#xD;
               3. Renal function: serum creatinine ≤ 1.5 ULN.&#xD;
&#xD;
          -  Fertile subjects (male and female) were required to receive effective medical&#xD;
             contraceptive measures until 3 months after the last study (see Annex 4 for specific&#xD;
             contraceptive measures).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who are known to have an allergic reaction to any component of the study drug；&#xD;
&#xD;
          -  Local treatments such as radiotherapy, radiofrequency ablation, intervention, etc or&#xD;
             surgical procedures (excluding prior diagnostic biopsy) in the 28 days before first&#xD;
             administration；&#xD;
&#xD;
          -  Known brain metastasis and/or leptomeningeal disease；&#xD;
&#xD;
          -  People with complete intestinal obstruction and incomplete intestinal obstruction&#xD;
             requiring treatment. However, patients whose obstruction is relieved by fistula or&#xD;
             stent placement can be included in the group;&#xD;
&#xD;
          -  Active severe clinical infection (&gt; Grade 2, NCI-CTCAE version 5.0), including active&#xD;
             tuberculosis；&#xD;
&#xD;
          -  Uncontrolled diabetes (fasting blood glucose ≥10 mmol/L), severe lung disease (such as&#xD;
             acute lung disease, pulmonary fibrosis that affects lung function, interstitial lung&#xD;
             disease. Except for radiation pneumonia that has recovered), liver failure；&#xD;
&#xD;
          -  Clinically significant cardiovascular diseases, such as heart failure (NYHAⅢ-Ⅳ),&#xD;
             uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, hypertension&#xD;
             (systolic blood pressure&gt;150mmHg and/or diastolic blood pressure&gt;100mmHg),&#xD;
             echocardiography The figure shows the ejection fraction &lt;50%, the history of&#xD;
             myocardial infarction within the past two years；&#xD;
&#xD;
          -  Renal replacement therapy；&#xD;
&#xD;
          -  &gt; Grade 1 Peripheral Nerve Disorder (NCI-CTCAE Version 5.0)；&#xD;
&#xD;
          -  History of organ allograft, autologous stem cell transplantation, or allogeneic stem&#xD;
             cell transplantation；&#xD;
&#xD;
          -  Previous malignancy other than CRC in the last 5 years except basal cell cancer of the&#xD;
             skin or preinvasive cancer of the cervix；&#xD;
&#xD;
          -  HIV infection, hepatitis B surface antigen positive (and peripheral blood hepatitis B&#xD;
             virus deoxynucleotide HBV DNA ≥ 1×10ˆ4 copy number/ml or ≥ 2000 IU/ml), hepatitis C&#xD;
             virus antibody positive (and peripheral blood hepatitis C virus nucleotide HCV RNA≥&#xD;
             1×10ˆ3 copies/ml or ≥ 200 IU/ml)；&#xD;
&#xD;
          -  Patients with coagulation dysfunction, meet any of the following conditions:&#xD;
             prothrombin time (PT) ≥ 1.5 ULN， thrombin time (TT) ≥ 1.5 ULN,activated partial&#xD;
             thromboplastin time (APTT) ≥ 1.5 ULN;&#xD;
&#xD;
          -  Previously treatment with VEGF pathway targeted therapy and EGFR monoclonal antibody；&#xD;
&#xD;
          -  Past treatment history:&#xD;
&#xD;
               1. Receiving other anti-tumor treatments (including anti-tumor treatments with&#xD;
                  traditional Chinese medicines, such as Aidi injection, Kanglaite injection,&#xD;
                  Kangai injection, cininobufosin, brucea javanica oil, etc.) within 4 weeks before&#xD;
                  the first administration of the study ；&#xD;
&#xD;
               2. Long-term systemic immunotherapy, or hormone therapy for anti-tumor purposes&#xD;
                  (physiological replacement therapy, except for those with hypothyroidism who take&#xD;
                  thyroxine);&#xD;
&#xD;
               3. Have received G-CSF, GM-CSF, whole blood or blood component transfusions within 4&#xD;
                  weeks before the first medication of the study;&#xD;
&#xD;
               4. Have received other experimental drugs or interventional clinical studies within&#xD;
                  4 weeks before the first medication of the study；&#xD;
&#xD;
          -  Pregnancy (confirmed by blood pregnancy test) or lactation；&#xD;
&#xD;
          -  There is currently alcohol or drug dependence；&#xD;
&#xD;
          -  There is a clear neurological disease or mental illness that has not been cured,&#xD;
             including epilepsy, dementia, schizophrenia, etc；&#xD;
&#xD;
          -  Adverse events of previous treatment (except for hair loss) did not return to grade 1&#xD;
             or below (NCI-CTCAE version 5.0)；&#xD;
&#xD;
          -  The researcher believes that the patient has other factors that affect the efficacy or&#xD;
             safety evaluation of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianming Xu, Professor</last_name>
    <phone>13910866712</phone>
    <email>jmxu2003@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nong Xu, Professor</last_name>
    <phone>13515715262</phone>
    <email>xunongclinictrial@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Xu, professor</last_name>
      <phone>13910866712</phone>
      <email>jmxu2003@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianming Xu</last_name>
      <phone>010-56943977</phone>
      <email>Hjc1126@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAS wild-type</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

